Fitting Emax models to clinical trial dose–response data when the high dose asymptote is ill defined. (16th September 2014)

• Record Type: Journal Article
• Authors: Brain, P.; Kirby, S.; Larionov, R.
• Is Part Of: Pharmaceutical statistics. Volume 13:Number 6(2014:Nov./Dec.)
• Page Start: 364
• Page End: 370
• Publication Date: 2014-09-16
• Subjects: Pharmacy -- Statistical methods -- Periodicals; Pharmacy -- Statistics -- Periodicals; 615.10727
• DOI: 10.1002/pst.1636
• Languages: English
• ISSNs: 1539-1604

Abstract

<abstract abstract-type="main" id="pst1636-abs-0001"> <title> <x xml:space="preserve">Abstract</x> </title> <p id="pst1636-para-0001">We consider fitting the so‐called Emax model to continuous response data from clinical trials designed to investigate the dose–response relationship for an experimental compound. When there is insufficient information in the data to estimate all of the parameters because of the high dose asymptote being ill defined, maximum likelihood estimation fails to converge. We explore the use of either bootstrap resampling or the profile likelihood to make inferences about effects and doses required to give a particular effect, using limits on the parameter values to obtain the value of the maximum likelihood when the high dose asymptote is ill defined. The results obtained show these approaches to be comparable with or better than some others that have been used when maximum likelihood estimation fails to converge and that the profile likelihood method outperforms the method of bootstrap resampling used. Copyright © 2014 John Wiley &amp; Sons, Ltd.</p> </abstract>